14 completed, 3 terminated, 1 active not recruiting. 12 Phase 2, 5 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 10, Terminated 2 |
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow FX006: new trials by email Literature Review of FX006 trials Research Report on FX006
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis FX006 - Trochanteric Bursitis | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 22 | 2020-08-12 | 2024-01-02 |
| Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis FX006, Normal Saline - Osteoarthritis of the Shoulder, Adhesive Capsulitis | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 19 | 2019-11-07 | 2024-01-24 |
| Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip FX006 32 mg - Osteoarthritis, Hip | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 16 | 2019-07-30 | 2024-01-24 |
| Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease FX006 Injection - Rotator Cuff Tears, Rotator Cuff Tendinitis | Phase 3 | Active not recruiting | Northwell Health | 65 | 2019-07-15 | 2024-12-27 |
| Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis FX006, Normal saline - Osteoarthritis, Hip | Phase 3 | Terminated | Pacira Pharmaceuticals, Inc | 70 | 2018-12-12 | 2024-01-24 |
| Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee FX006 32 mg - Osteoarthritis, Knee | Phase 3 | Completed | Pacira Pharmaceuticals, Inc | 129 | 2018-04-24 | 2024-01-24 |
| The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA Zilretta - Knee Osteoarthritis | Phase 4 | Completed | University of Kansas Medical Center | 70 | 2018-03-19 | 2022-05-05 |
| Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip FX006 32 mg, TAcs 40 mg - Osteoarthritis of the Shoulder, Osteoarthritis of the Hip | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 55 | 2017-12-18 | 2024-01-24 |
| Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA FX006 32 mg, TAcs 40 mg - Bilateral Knee Osteoarthritis | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 24 | 2017-12-06 | 2024-01-24 |
| Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee FX006 32 mg - Osteoarthritis of the Knee | Phase 3 | Completed | Pacira Pharmaceuticals, Inc | 208 | 2017-02-20 | 2024-01-24 |
| Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes FX006 32 mg, TCA IR 40 mg - Osteoarthritis of the Knee, Type 2 Diabetes Mellitus | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 33 | 2016-04-01 | 2024-01-24 |
| Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee FX006 32 mg, TCA IR 40 - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 81 | 2015-11-01 | 2024-01-24 |
| Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee FX006 32 mg, TCA IR 40 mg - Post-traumatic Osteoarthritis of the Knee | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 6 | 2015-02-01 | 2024-01-24 |
| Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee FX006, Placebo, TCA IR 40 - Osteoarthritis of the Knee | Phase 3 | Completed | Pacira Pharmaceuticals, Inc | 486 | 2015-01-01 | 2024-01-24 |
| Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee FX006 32 mg, Placebo, FX006 16 mg - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 310 | 2014-04-01 | 2024-01-24 |
| Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee FX006 10 mg, FX006 40 mg, TCA IR 40 mg - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 50 | 2013-11-01 | 2024-01-24 |
| Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee FX006 10 mg, FX006 40 mg, FX006 60 mg - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 24 | 2012-07-01 | 2024-01-24 |
| Study of FX006 in Patients With Osteoarthritis of the Knee FX006, TCA IR - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 229 | 2012-06-01 | 2024-01-24 |
Osteoarthritis (15) · Pain (12) · Osteoarthritis, Knee (10) · Osteoarthritis, Hip (3) · Bursitis (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Rotator Cuff Injuries (1) · Shoulder Impingement Syndrome (1)
Pacira Pharmaceuticals, Inc (15) · Northwell Health (1) · The University of Texas Health Science Center, Houston (1) · University of Kansas Medical Center (1)
United States (17) · Australia (3) · Canada (3) · Denmark (1) · Estonia (1) · Hong Kong (1) · Lithuania (1) · Romania (1) · United Kingdom (1)
Neil Bodick, MD (7) · Scott Kelley, MD (6) · Neil A Segal, MD (1) · Neil Bodick, MD, PhD (1) · Pritish Bawa, MD (1) · Russell Camhi (1) · Scott Kelley (1)
PMID 29088579, PMID 29664865, PMID 30203101, PMID 30741382, PMID 30968336, PMID 31662801, PMID 34350546, PMID 34791634, PMID 35258839